The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, J.
Right arrow Articles by Finnegan, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, J.
Right arrow Articles by Finnegan, A.
The Journal of Immunology, 2003, 170: 3495-3503.
Copyright © 2003 by The American Association of Immunologists

IL-4 Potentiates Activated T Cell Apoptosis Via an IL-2-Dependent Mechanism 1

Jian Zhang2,*,{ddagger}, Tamás Bárdos3,*, Qing Shao3,¶, Jurg Tschopp||, Katalin Mikecz*,{ddagger},§, Tibor T. Glant*,{dagger},§ and Alison Finnegan{dagger},{ddagger}

* Section of Biochemistry and Molecular Biology, Department of Orthopedic Surgery, and Departments of {dagger} Internal Medicine, {ddagger} Immunology/Microbiology, and § Biochemistry, Rush University at Rush-Presbyterian-St. Luke’s Medical Center, Chicago, IL 60612; Department of Anatomy and Cell Biology, University of Western Ontario, London, Ontario, Canada; and || Institute of Biochemistry, University of Lausanne, Epalinges, Switzerland


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Activation-induced cell death (AICD) of T cells is one of the major mechanisms of peripheral tolerance. The regulation of AICD by IL-4 is poorly understood. In this study, we report that AICD in IL-4-deficient T cells is significantly reduced compared with that in wild-type T cells. This impaired AICD correlates with the failure to induce degradation of cellular FLIP. IL-4-mediated enhancement of AICD and cellular FLIP degradation requires a Janus kinase/STAT-6 signaling pathway. Unexpectedly, these effects of IL-4 could be blocked by a neutralizing anti-IL-2 Ab, and addition of rIL-2 could completely restore the defective AICD in IL-4-deficient T cells. Furthermore, IL-4 regulates the T cell thresholds for IL-2 signaling during AICD. These data suggest that IL-4 promotes AICD via an IL-2-dependent mechanism.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Interleukin-4 is a cytokine produced by T cells, mast cells, and basophils that controls cell growth and regulates the immune system (1). IL-4 mediates its function through the binding to and stimulation of the IL-4R. The IL-4R consists of IL-4R{alpha}, which binds IL-4 with high affinity, and the common {gamma}-chain ({gamma}c) 4 shared by IL-2, IL-7, IL-9, and IL-15 receptors (2, 3, 4). Binding of IL-4 to the IL-4R triggers phosphorylation of Janus kinase (JAK)-1 and JAK-3 (2, 3, 5, 6) leading to the activation of two major signaling pathways known as STAT-6, and insulin receptor substrates (IRS) which include IRS-1 and IRS-2 (2, 3). Tyrosine phosphorylated STAT-6 forms homodimers and translocates to the nucleus where they bind IL-4 responsive elements (2, 3). Recent studies using STAT-6-deficient (STAT-6-/-) (3) mice have demonstrated that many IL-4-mediated effects on gene expression require the activation of STAT-6 (2, 3).

Activation-induced cell death (AICD) results from repeated stimulation through the TCR with Ags or anti-TCR Ab, and is dependent upon the interaction between Fas and Fas ligand (FasL) (7, 8, 9, 10, 11, 12). Fas-mediated AICD is an important mechanism for maintaining tolerance to self-Ag (13). Ligation of Fas with FasL induces trimerization of the Fas receptor, and the adaptor protein, Fas-associated death domain protein (FADD), binds to the trimerized Fas cytoplasmic region through the interaction of the respective death domains. Pro-caspase-8 (also called FLICE) is then recruited to FADD through binding of the death effector domains, which in turn induces self-activation of caspase-8. The Fas receptor, FADD, and pro-caspase-8 form a functional death-inducing signaling complex (DISC). The activated caspase-8 is released into the cytosol where it results in activation of a caspase cascade that initiates apoptosis (11, 14, 15, 16, 17). Recently, a new family of viral FLIP has been described, which interferes with caspase-8 recruitment to the death effector domains of FADD (18). Subsequently, a cellular homolog of viral FLIP has been identified by several groups and variously named c-FLIP, Casper, inhibitor of FLICE, caspase homologue, FADD-like anti-apoptotic molecule, MORT1 associated CED-3 homolog-regulated inducer of toxicity, caspase-like apoptosis-regulatory protein, or usurpin (19, 20, 21, 22, 23, 24, 25, 26). During Fas-mediated signaling, c-FLIP is recruited to the DISC and interferes with the recruitment of pro-caspase-8, thereby inhibiting Fas-induced apoptosis (19, 27, 28, 29).

Cytokines play an important role in the regulation of T cell apoptosis, but the specific role of IL-4 in the regulation of AICD is controversial. The defective AICD in IL-2R{alpha}-/- T cells cannot be corrected by IL-4 (30). However, a high dose of IL-4 (100 ng/ml) has been shown to potentiate AICD in IL-2-/-, IL-2R{alpha}-/-, and IL-2R{beta}-/- T cells (31, 32). Therefore, whether and how IL-4 regulates AICD, especially in the presence of IL-2, remains to be further elucidated. In this study, we attempted to solve this discrepancy by comparing the levels of AICD in wild-type (Wt) T cells with those in IL-4-/- and STAT-6-/- T cells. We demonstrate that IL-4 regulates T cell susceptibility to AICD by an IL-2-dependent mechanism which possibly involves induction of c-FLIP degradation. Our observations indicate that IL-4 is not only a growth factor of T cells, but also an enhancer of AICD.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Mice

Wt and IL-4-/- BALB/c mice were purchased from The Jackson Laboratory (Bar Harbor, ME). The STAT-6-/- mice described previously (33) were backcrossed into a BALB/c background for 12 generations and then maintained as a homozygote colony in our animal facility. C57BL/6 mice were purchased from National Cancer Institute (Frederick, MD). c-FLIPL transgenic (Tg) mice (C57BL/6 background) were described previously (34). All mice used in these experiments were 6–10 wk old.

Reagents and cell culture

The following reagents were purchased from BD PharMingen (San Diego, CA): anti-CD3 (145-2C11), anti-CD28 (37.51), PE-conjugated anti-FasL (MFL-3), FITC-conjugated and purified anti-Fas (Jo2), PE-conjugated anti-CD3 (145-2C11), PE-conjugated anti-IL-2R{gamma} mAbs and FITC-conjugated annexin V. Anti-Bcl-2 (C-2) and Bcl-xS/L (L-19), anti-FADD (S-18), and anti-caspase-8 (T-16) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-c-FLIPL/S mAb (DAVE-2) was purchased from Alexis (San Diego, CA). Recombinant mouse (rm) IL-4, recombinant human (rh) IL-2, propidium iodide (PI), streptavidin, and anti-actin Ab (AC40) were purchased from Sigma-Aldrich (St. Louis, MO). A mouse Fas-Fc chimeric protein, rhlgG Fc, rmFasL which is generated from a DNA sequence encoding amino acid residues 132–279 of mouse FasL fused to the signal peptide of human CD33 and six histidine residues, T cell enrichment columns, anti-IL-4, anti-IL-2, anti-6X histidine, and fluorokine-conjugated rhIL-2 kit were obtained from R&D Systems (Minneapolis, MN). Lympholite-M was purchased from Cedarlane Laboratories (Hornby, Ontario, Canada). HRP-conjugated goat-anti-rabbit IgG, HRP-conjugated goat-anti-mouse IgG, and HRP-conjugated goat-anti-rat IgG Abs were purchased from Kirkegaard & Perry Laboratories (Gaithersburg, MD). Benzyloxycarbonyl (Cbz)-Val-Ala-Asp(OMe)-fluoromethylketone (zVAD-FMK) was purchased from Calbiochem (San Diego, CA). Sybr green I nucleic acid fluorescent dye was purchased from BioWhittaker Molecular Application (Rockland, ME). One step RT-PCR kit was obtained from Qiagen (Valencia, CA).

T cell isolation and activation

Splenic T cells from naive Wt, IL-4-/-, and STAT6-/- mice were isolated (purity >=95% as determined by FACScan analysis of CD3+ cell surface expression) on T cell enrichment columns (R&D Systems). For in vitro activation, T cells (2 x 106/ml) were stimulated with plate-bound anti-CD3 (2 µg/ml) and anti-CD28 (1 µg/ml) mAbs in 24-well plates, and then cultured for 72 h in RPMI 1640 supplemented with 10 mM HEPES, 0.1 mg/ml streptomycin, 100 U/ml penicillin, 0.05 mM 2-ME, 2 mM glutamine (all purchased from Life Technologies, Grand Island, NY) in the presence of 10 U/ml rhIL-2. Viable cells were separated from dead cells by Lympholite-M, and were then subjected for restimulation. Viability of cells was determined by PI staining.

Proliferation assay

Splenic T cells (2 x 106/ml) from Wt, IL-4-/-, and STAT-6-/- mice were stimulated for 48 h at 37°C in round bottom 96-well plates precoated with anti-CD3 mAb (2 µg/ml) and anti-CD28 (1 µg/ml) mAbs. The cells were pulsed with 1 µCi [3H]thymidine, and harvested 16 h later. The radioactivity was quantitated using a Wallac 1205 Betaplate beta liquid scintillation counter (Gaithersburg, MD).

Induction and analysis of AICD

In vitro activated splenic T cells (2 x 106) were restimulated with either plate-bound anti-CD3 for 8 h in the presence of 10 U/ml rhIL-2 or immobilized rmFasL for 6 h. To identify apoptotic cells specifically, a combination of FITC-conjugated annexin V and PI staining was used as described previously (35). Annexin V binds to phosphatidylserine exposed on the outer leaflet of the plasma membrane early in apoptosis, whereas PI, a marker of membrane permeability, is a late-stage event common to both apoptosis and necrosis. The annexin V/PI-stained cells were immediately analyzed using a FACScan (BD Biosciences, Mountain View, CA). To induce the DISC formation, preactivated splenic T cells were incubated on ice for 30 min with rmFasL, and cross-linked for 0, 1, 5, and 15 min at 37°C with anti-6X histidine mAb (35).

Immunoprecipitation and Western blot

Restimulated T cells were lysed in ice cold 1% Brij 97 or Triton X-100 containing lysis buffer (10 mM Tris, pH 7.5, 150 mM NaCl, 2 mM EGTA, 50 mM {beta}-glycerophosphate, 2 mM Na3VO4, 10 mM NaF, 1 mM DTT, 1 mM PMSF, 10 µg/ml leupeptin, and 10 µg/ml apoptinin). Protein concentrations in the cell lysates were determined using a bicinchoninic acid assay kit (Pierce, Rockford, IL). Cell lysates were precleared, and postnuclear cell lysates were normalized for protein concentration levels and immunoprecipitated (3 h, 4°C) with the specific polyclonal Abs or control isotype-matched preimmune Ig precoupled to 25 µl of protein A/G CL-4B Sepharose (Amersham Pharmacia Biotech, Uppsala, Sweden). The immunoprecipitates were resolved on SDS-PAGE and transferred to nitrocellulose membranes (Hybond C Super; Amersham, Piscataway, NJ). Alternatively, 30 µg of proteins from cell lysates were separated by SDS-PAGE. Blots were blocked for 1 h at room temperature in PBS containing 2% BSA and 0.05% Tween 20. Membranes were incubated overnight with specific Abs, then washed three times in PBS containing 0.05% Tween 20, and detected using HRP-conjugated secondary Abs. After three washes in PBS containing 0.05% Tween 20, signals were revealed by an ECL detection system (Amersham) and visualized by autoradiography.

Flow cytometric analysis

Wt and IL-4-/- T cells were activated with plate-bound anti-CD3 and anti-CD28 in the presence of 10 U/ml rhIL-2, and Fas expression was detected using flow cytometry. Preactivated splenic T cells from IL-4-/- mice were restimulated as indicated in the presence of rhIL-2 (10 or 2 U/ml). The cells were collected, washed two times with PBS containing 1% BSA and 0.05% sodium azide, and then incubated with FITC-conjugated anti-Fas or PE-conjugated anti-FasL mAb (MFL-3; BD PharMingen) for 45 min at 4°C. After rinsing twice with PBS, cells were fixed in PBS and 1% paraformaldehyde, and the staining was assessed by a FACScan flow cytometer with CellQuest software (BD Biosciences). An isotype-matched control Ab served to define background values.

To analyze IL-2R expression, purified IL-4-/- splenic T cells were stimulated for 72 h with plate-bound anti-CD3 and anti-CD28 mAbs in the presence or absence of 10 U/ml rhIL-2 with different concentrations of rmIL-4 (5–60 ng/ml), or in the presence of rhIL-2 (5–60 U/ml). By the end of the cultures, cells were harvested, and stained with biotin-labeled rhIL-2 followed by avidin-FITC. The expression of total IL-2R was determined by flow cytometry. To detect {gamma}c chain expression, IL-4-/- T cells were activated for 72 h with anti-CD3 and anti-CD28 in the presence of rhIL-2 (10 U/ml) with various amounts of rmIL-4 as described above, and {gamma}c chain expression was determined.

Quantitative real-time RT-PCR assays of c-FLIP

Total RNA was purified from cells by a guanidinium isothyocyanate/silica gel-based membrane RNeasy method (Qiagen) according to the manufacturer’s instructions. The primers were designed using the Primer Express software package that accompanies the ABI PRISM 7900HT sequence detection System (Applied Biosystems, Foster City, CA) based upon the sequences of mouse c-FLIPL and c-FLIPS from GenBank Accession No.U97076 and Y14042. The forward primer of c-FLIPL was 5'-TGGACAAAGTGTATGCGTGGAA and the reverse primer was 5'-TCACGTAGGAGCCAGGATGAGT. The forward primer of c-FLIPS was 5'-GGC CAGCTCTTTTGCTACCT and the reverse primer was 5'-TCCTCCACGGTTGCTTTGTCT. The real-time RT-PCR was performed using the Qiagen one-step RT-PCR kit. The DNA-intercalating SYBR green I fluorescent dye was used for detection of the PCR product. To verify that equivalent amounts of RNA were added to each c-FLIP PCR, PCR amplification of the GAPDH housekeeping gene was performed in each sample. The forward primer of GAPDH was 5'-CCATGGAGAAGGCTGGGG-3' and the reverse primer was 5'-CAAAGTTGTCATGGATGACC-3'. RT-PCR was performed as follows: reverse transcription reaction, 50°C for 30 min and 95°C for 15 min; PCR amplification: 94°C for 30 s; 55°C for 30 s; 72°C for 30 s, repeated for 40 cycles (ABI PRISM 7900HT sequence detection System; Applied Biosystems).

The relative differences among the samples at different time points were determined using the {Delta}{Delta}CT (CT: cycle threshold) method as outlined in the Applied Biosystems protocol for RT-PCR. A {Delta}CT value was calculated for each sample using the CT value for GAPDH to account for loading differences in the RT-PCR and the CT values for the input DNA samples to normalize the c-FLIPL or c-FLIPS results. A {Delta}{Delta}CT value was then calculated by subtracting the {Delta}CT for the control (day 0) from each time point {Delta}CT within an experiment. The {Delta}{Delta}CT values were converted to fold differences compared with the control (day 0 sample) by raising 2 to the -{Delta}{Delta}CT power (2-{Delta}{Delta}CT).

Detection of IL-2 and IL-4 production

Splenic T cells from Wt and IL-4-/- mice were cultured for 48 h in wells coated with anti-CD3 and anti-CD28, and culture supernatants were collected for determining cytokine concentrations. The IL-2 and IL-4 concentrations in the supernatants were determined by ELISA (BD PharMingen).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
IL-4-mediated potentiation of TCR-induced AICD is STAT-6-dependent

To assess the effects of IL-4 on AICD of T cells, Wt T cells were stimulated for 72 h with plate-bound anti-CD3 and anti-CD28 mAbs with 10 U/ml rhIL-2 in the presence or absence of neutralizing anti-IL-4 mAb (30 µg/ml), and activated T cells were then restimulated for 8 h with plate-bound anti-CD3 with or without anti-IL-4 in the presence of 10 U/ml rhIL-2. The apoptotic cells were detected by staining of FITC-conjugated annexin V and PI. Apoptotic cells are scored as annexin V+PI-, whereas necrotic cells are annexin V+PI+. A significant number of Wt T cells restimulated for 8 h with plate-bound anti-CD3 underwent early apoptosis which was annexin V-positive but PI-negative. As shown in Fig. 1A, specific TCR-mediated AICD was significantly abrogated in the presence of a neutralizing anti-IL-4, suggesting that IL-4 plays an important role in the induction of AICD. To further confirm this observation, TCR-mediated AICD was examined in IL-4-/- mice. Consistent with the above result, AICD in T cells lacking IL-4 was significantly impaired compared with that in Wt T cells (Fig. 1B). Furthermore, the defective AICD observed in IL-4-/- T cells was not due to a higher activation threshold because high concentrations of anti-CD3 stimulation (5–10 µg/ml) did not restore the impairment in AICD in IL-4-/- T cells. Taken together, the above observations suggest that IL-4 promotes AICD in T cells.



View larger version (36K):
[in this window]
[in a new window]
  		FIGURE 1. IL-4 potentiates AICD of T cells. A, Splenic T cells from BALB/c mice were activated for 72 h with 2 µg/ml plate-bound anti-CD3 and anti-CD28 Abs in the presence of 10 U/ml rhIL-2 with or without 30 µg/ml anti-IL-4 mAb. Viable cells were collected and restimulated for 8 h with plate-bound anti-CD3 mAb in the presence of 10 U/ml rhIL-2 with or without anti-IL-4 mAb. B, Wt and IL-4-/- T cells were activated for 72 h as described above, and restimulated for 8 h with different concentrations of plate-bound anti-CD3 (0.001–10 µg/ml) in the presence of 10 U/ml rhIL-2. C, Wt, IL-4-/-, and STAT-6-/- T cells were activated and restimulated in the presence of 10 U/ml rhIL-2 with or without rmIL-4. D and E, Wt and IL-4-/- T cells were activated for 72 h as in A, and viable cells were then stimulated with immobilized anti-CD3 in the presence of Fas-Fc (50 µg/ml) or rhIgG1 Fc for 8 h (D) or rmFasL (1 µg/ml) for 6 h (E). Apoptotic cells were determined by flow cytometry using double-staining of FITC-conjugated annexin V and PI (A–E). F, Splenic T cells from Wt, IL-4-/-, and STAT-6-/- mice were cultured for 72 h in wells coated with anti-CD3 (2 µg/ml) and anti-CD28 (1 µg/ml), and T cell proliferation was determined using [3H]thymidine incorporation. G, Wt and IL-4-/- T cells were activated and restimulated as in A but without exogenous IL-2. Apoptotic cells were determined. Data are from one representative of three independent experiments.

 
Upon IL-4R ligation, STAT-6 is tyrosine phosphorylated by JAK-1 and JAK-3, homodimerizes, and then translocates to the nucleus (1, 2, 3). We then hypothesized that IL-4-mediated regulation of AICD may be involved in the JAK/STAT-6 signaling pathway. To test this possibility, AICD levels in Wt, IL-4-/-, and STAT-6-/- T cells were compared. As shown in Fig. 1C, T cells from STAT-6-/- mice were also resistant to AICD, indicating that IL-4 regulates AICD via the JAK/STAT-6 signaling pathway. To further confirm this finding, IL-4-/- and STAT-6-/- T cells were activated and then restimulated with anti-CD3 in the presence of rmIL-4. As expected, rmIL-4 did restore the defective AICD in IL-4-/- T cells but not in STAT-6-/- T cells (Fig. 1C). IL-4-mediated restoration of AICD in IL-4-/- T cells is regulated by Fas-FasL interaction because a mouse Fas-Fc chimeric protein significantly abrogated this enhancement (Fig. 1D). To further confirm whether defective Fas-mediated signaling existed in IL-4-/- T cells, Wt and IL-4-/- T cells were preactivated as described above, restimulated for 6 h at 37°C with cross-linked rmFasL, and the apoptotic cells were determined. Consistent with Fig. 1C, FasL-induced T cell death in IL-4-/- mice was significantly impaired (Fig. 1E). It has also been shown that cytokines stimulating cell division will allow cells to become sensitive to AICD (31, 36). Thus, it is critical to know the cell cycle status of IL-4-/- and STAT-6-/- T cells under these conditions. To this end, a thymidine uptake assay was performed. As shown in Fig. 1F, the rates of IL-4-/- and STAT-6-/- T cell proliferation were comparable or even higher than those of Wt T cells. This finding suggests that there may be a special role of IL-4 signaling in priming T cells for AICD. We should note that the induction of AICD in Wt T cells does not require exogenous IL-2 (Fig. 1G) (37), whereas AICD of IL-4-/- T cells requires medium levels of IL-2 plus exogenous IL-4 (Fig. 1C).

IL-4 up-regulates FasL expression but does not affect Bcl-2 expression

AICD is mediated by Fas-FasL interaction (9, 10, 37). The expression of Fas or FasL on T cells might affect the susceptibility of T cells to AICD. However, we could not detect any difference in Fas expression between Wt and IL-4-/- T cells after primary CD3/CD28 stimulation (data not shown). It has been shown that FasL expression requires CD3 restimulation (35) and IL-2 can up-regulate FasL expression during primary stimulation (37). We then detected FasL expression after CD3 restimulation in the presence of 10 U/ml rhIL-2. There was no difference of FasL expression observed in Wt and IL-4-/- T cells (Fig. 2, upper panel). This is possibly due to the presence of 10 U/ml rhIL-2 which may be sufficient for induction of FasL expression in IL-4-/- T cells. To test whether this was the case, activated Wt and IL-4-/- T cells were restimulated for 24 h with anti-CD3 in the presence of 2 U/ml rhIL-2, and FasL expression was determined by flow cytometry. IL-4-/- T cells expressed significantly low levels of FasL at the cell surface compared with Wt T cells (Fig. 2A, lower panel). These observations suggest that IL-4 can up-regulate FasL expression induced by IL-2, but the defective AICD in IL-4-/- T cells cannot be ascribed to the defective expression of FasL because equivalent levels of FasL expression were observed at the concentration (10 U/ml) of rhIL-2 used in Wt and IL-4-/- T cells.



View larger version (43K):
[in this window]
[in a new window]
  		FIGURE 2. IL-4 up-regulates FasL expression but does not affect Bcl-2 and Bcl-xL expression. A, Wt and IL-4-/- T cells were activated and restimulated as in Fig. 1A in the presence of either 10 or 2 U/ml rhIL-2. Expression of FasL on restimulated, gated viable T cells was determined. B, Splenic T cells purified from Wt and IL-4-/- mice were activated for 0, 24, 48, and 72 h in the presence of 10 U/ml rhIL-2. The cells were harvested at each time point, lysed in 1% Triton X-100, and blotted with anti-Bcl-2 and anti-Bcl-xL, respectively. The loading control was performed using anti-actin immunoblotting. The data are from one of three independent experiments.

 
IL-4 has been shown to inhibit death in resting T cells and suppresses superantigen-induced T cell death by preventing degradation of Bcl-2 and Bcl-xL (38, 39). Therefore, it was important to determine whether decreased expression of Bcl-2 and Bcl-xL was involved in IL-4-mediated promotion of T cell AICD. Splenic T cells from Wt and IL-4-/- mice were cultured in wells coated with anti-CD3 and anti-CD28 for 0, 24, 48, and 72 h in the presence of 10 U/ml rhIL-2. The cells were lysed, and the cellular proteins were blotted with anti-Bcl-2 and Bcl-xL Abs, respectively. No change in the amounts of Bcl-2 or Bcl-xL was seen in IL-4-/- T cells compared with that in Wt T cells (Fig. 2B), suggesting that Bcl-2 and Bcl-xL may not be involved in the regulation of susceptibility of T cells to Fas-mediated AICD.

Enhancement of AICD by IL-4 correlates with increased c-FLIP degradation

It has been shown that c-FLIP associates with FADD following Fas ligation, and functions as an inhibitor of Fas-mediated apoptosis through its interference with the recruitment of caspase-8 to FADD (19, 27, 28, 29, 37, 40, 41, 42). Therefore, c-FLIP may determine the susceptibility of T cells to AICD. To analyze the effect of IL-4 on c-FLIP expression during TCR-mediated AICD, Wt and IL-4-/- T cells were activated with a combination of plate-bound anti-CD3 and anti-CD28 mAbs for 0, 24, 48, and 72 h in the presence of 10 U/ml rhIL-2. Aliquots of cells were harvested at each time point, and RNA was extracted and assayed for c-FLIP transcripts by real-time RT-PCR. No decreases but slight increases in both c-FLIPL and c-FLIPS mRNA expression was observed after CD3/CD28 stimulation (Fig. 3A). These findings suggest that IL-4 may not control c-FLIP expression at the transcriptional level.



View larger version (60K):
[in this window]
[in a new window]
  		FIGURE 3. Resistance of IL-4-/- T cells to AICD correlates with the failure of inducing c-FLIP degradation. A, Wt and IL-4-/- splenic T cells were stimulated for 0–72 h with plate-bound anti-CD3 and anti-CD28 mAb in the presence of 10 U/ml rhIL-2. RNA was isolated from all samples, and aliquots from each time point were subjected to c-FLIPL and c-FLIPS mRNA analysis by real-time RT-PCR using a one-step PCR kit from Qiagen. For comparison of RT-PCR results for each time point from Wt and IL-4-/- T cells, a relative quantitation using the comparative CT method was applied. B, Wt and IL-4-/- T cells, either treated with 60 ng/ml rmIL-4 or left untreated, were stimulated as in Fig. 1A. Cells were collected at 0, 24, 48, and 72 h, and lysed in 1% Triton X-100 lysis buffer. The cell lysates were blotted with anti-c-FLIPL/S mAb. The membranes were stripped and reprobed with anti-actin mAb. C, Wt T cells were activated for 24 or 72 h in the presence or absence of a pan-caspase inhibitor zVAD (50 µM). The cell lysates were blotted with anti-c-FLIPL/S. D, Splenic T cells from Wt and IL-4-/- mice were activated for 72 h as described in Fig. 1A. Activated T cells were then incubated for 30 min with recombinant mouse FasL, followed by cross-linking for 0, 1, 5, and 15 min with anti-6X histidine, and lysed in 1% Brij 97 lysis buffer. The DISC was immunoprecipitated with anti-Fas, and determined by immunoblotting with anti-c-FLIPL/S, anti-caspase-8, anti-FADD, and anti-Fas Abs, respectively. E, Splenic T cells from C57BL/6 and c-FLIPL Tg mice were preactivated in Fig. 1A. Activated T cells were ligated for 6 h with cross-linked smFasL, and apoptotic cells were determined. The transgenic expression of c-FLIPL was determined using anti-Flag mAb. Similar results were obtained in three independent experiments.

 
To investigate how IL-4 regulates c-FLIP expression in the presence of IL-2, splenic T cells from Wt and IL-4-/- mice were stimulated for 0–72 h with plate-bound anti-CD3 and anti-CD28 mAb in the presence of 10 U/ml rhIL-2. The activated T cells were collected at each time point, and c-FLIP expression was assessed by immunoblotting with anti-c-FLIPL/S mAb. As shown in Fig. 3B, in Wt T cells a degradation of both c-FLIPL and c-FLIPS occurred at 48 h, being evident at 72 h after stimulation, whereas in IL-4-/- T cells c-FLIP degradation was significantly reduced (Fig. 3B). To further determine whether c-FLIP degradation was induced by caspase activation, Wt T cells were pretreated for 15 min with zVAD-FMK, a pan-caspase inhibitor, and then stimulated for 24 and 72 h with anti-CD3 and anti-CD28 in the presence of 10 U/ml rhIL-2. As shown in Fig. 3C, the degradation of c-FLIPL and c-FLIPS was significantly inhibited in zVAD-treated Wt T cells. These results clearly indicate that IL-4 does not regulate c-FLIP expression at the transcriptional levels but rather favors c-FLIP degradation. Furthermore, the presence of rmIL-4 favored c-FLIP degradation in IL-4-/- T cells (Fig. 3B). These observations suggest that IL-4 directly or indirectly controls c-FLIP expression at the posttranslational level, and might mediate the susceptibility of T cells to AICD. In support of this hypothesis, addition of exogenous IL-4 restored AICD in IL-4-/- T cells to a comparable level with that of Wt T cells (Fig. 1C).

Following ligation of the FasR with FasL, Fas, FADD, and pro-caspase-8 form a DISC. c-FLIP recruited to the DISC determines the susceptibility of T cells to Fas-mediated apoptosis (19, 27, 28, 29, 37, 40, 41, 42). Therefore, in IL-4-/- T cells enhanced recruitment of c-FLIP to the DISC may preclude pro-caspase-8 recruitment to the DISC thereby preventing apoptosis. To test this possibility, splenic T cells from Wt and IL-4-/- mice were activated for 72 h with plate-bound anti-CD3 and anti-CD28 in the presence of rhIL-2, and activated T cells were incubated for 30 min on ice with rmFasL, followed by cross-linking at 37°C for 1, 5, and 15 min with anti-6X histidine mAb or were left uncross-linked (35). The cells were lysed, immunoprecipitated with anti-Fas, and blotted with anti-caspase-8, anti-c-FLIPL/S, anti-FADD and anti-Fas, respectively. As shown in Fig. 3D, following ligation of Fas with FasL, high amounts of c-FLIPL and c-FLIPS were recruited to the DISC in IL-4-/- T cells. This recruitment was significantly impaired in Wt T cells, and the only c-FLIP that could be detected in the DISC was p43 intermediates of c-FLIPL. Although pro-caspase-8 was detected at the DISC in IL-4-/- T cells, the amounts of pro-caspase-8 and active p20 fragments were significantly reduced (Fig. 3D). In contrast, pro-caspase-8 and its p43 intermediates and active p20 fragments were present in Wt T cells after FasL stimulation (Fig. 3D). Our data suggest that c-FLIP prevents pro-caspase-8 recruitment to the DISC.

To further confirm the role of c-FLIP in Fas-mediated T cell death, c-FLIPL Tg mice were generated to show increased expression of c-FLIPL in T cells under the control of the T cell-specific human CD2 enhancer element (34). T cells from Wt C57BL/6 and c-FLIPL Tg mice were preactivated for 72 h with plate-bound anti-CD3 and anti-CD28 in the presence of 10 U/ml rhIL-2. Activated T cells were then stimulated with immobilized rmFasL for 6 h, and apoptotic cells were determined. c-FLIPL Tg T cells were significantly resistant to Fas-mediated cell death compared with Wt T cells (Fig. 3E). These results indicate that c-FLIP is indeed involved in Fas-mediated cell death in T cells. Note that a small but significant number of T cells from c-FLIPL Tg mice still underwent apoptosis, suggesting that c-FLIPS may also play a role in the regulation of T cell susceptibility to Fas-mediated cell death in T cells.

IL-4 regulates the sensitivity of T cells to AICD via an IL-2-dependent mechanism

Previous studies suggested that IL-2 predisposes T cells to Fas-mediated AICD (37, 43). IL-2 regulates the susceptibility of T cells to Fas-mediated AICD via the down-regulation of c-FLIP expression (37, 43). To test whether degradation of c-FLIP in Wt T cells correlated with increased IL-2 and IL-4 production, the kinetics of IL-2 and IL-4 production by Wt T cells stimulated with anti-CD3 and anti-CD28 were determined. As shown in the upper and middle panels of Fig. 4A, time-dependent increase in IL-2 and IL-4 production and IL-2R expression was observed in Wt T cells, being highest at 72 h following stimulation which correlates with significant degradation of c-FLIP (Fig. 3B). Because it has been shown that IL-2 is a critical cytokine for induction of AICD, it is possible that IL-4 may promote AICD via the increased secretion of IL-2. To test this possibility, IL-2 production during the primary stimulation with anti-CD3 and anti-CD28 mAbs was determined by ELISA. IL-2 production in activated Wt and IL-4-/- T cells was equivalent (Fig. 4A, lower panel). Our data indicate that the production of IL-2 by CD3/CD28-triggered T cells was significantly higher at 48 and 72 h than 24 h. However, an equivalent amount of IL-2 production by IL-4-/- T cells in response to CD3/CD28 stimulation cannot completely rule out the possibility that, in the absence of IL-4, the sensitivity of T cells to IL-2 may be decreased. If this is the case, exogenous IL-2 should restore the defective AICD in IL-4-/- T cells. Indeed, the addition of rhIL-2 restored defective AICD observed in IL-4-/- T cells in a dose-dependent manner (Fig. 4B), suggesting that the role of IL-4 in AICD may be mediated by IL-2. In support of this observation, IL-4-mediated restoration of defective AICD in IL-4-/- T cells was abrogated by a neutralizing anti-IL-2 mAb (Fig. 4B). Most importantly, IL-2R expression in IL-4-/- T cells was significantly reduced after anti-CD3 and anti-CD28 stimulation (Fig. 4C, left panel). Taken together, our observations indicate that IL-4 may regulate the sensitivity of T cells to IL-2 during the induction of AICD possibly via the up-regulation of IL-2R expression.



View larger version (37K):
[in this window]
[in a new window]
  		FIGURE 4. IL-4 regulates IL-2R expression during AICD in IL-4-/- T cells. A, Top panel, Wt T cells were stimulated for 24, 48, and 72 h with plate-bound anti-CD3 and anti-CD28 mAbs; IL-2 and IL-4 production in the culture supernatants was detected by ELISA; IL-2R expression was detected by staining T cells with biotinylated rhIL-2 followed by avidin-FITC; and IL-2R expression was determined using flow cytometry (middle panel). Bottom panel, Wt and IL-4-/- T cells were activated for 72 h with plate-bound anti-CD3 and anti-CD28 mAbs. IL-2 content in the supernatants was determined. B, Splenic T cells from Wt, IL-4-/-, and STAT-6-/- mice were activated and restimulated as Fig. 1A in the presence of 10 U/ml rhIL-2. Some of the IL-4-/- T cells were treated with rmIL-4 (60 ng/ml), rhIL-2 (10–60 U/ml), or rmIL-4 (60 ng/ml) plus anti-IL-2 (50 µg/ml). STAT-6-/- T cells were treated with rhIL-2 (10–60 U/ml). Apoptotic cells were scored as in Fig. 1A. C, Left panel, Wt and IL-4-/- T cells were stimulated as in Fig. 1A, and IL-2R expression was determined. Middle panel, IL-4-/- T cells were cultured for 72 h in the presence or absence of 10 U/ml rhIL-2 with different concentrations of rmIL-4 (5–60 ng/ml) (IL-2/IL-4 or IL-4), or in the presence of different concentrations of rhIL-2 (5–60 U/ml) with or without rmIL-4 (60 ng/ml) (IL-2/IL-4 or IL-2). Total IL-2R expression was determined. Right panel, IL-4-/- T cells were activated for 72 h with 10 U/ml rhIL-2 with different concentrations of rmIL-4 (5–60 ng/ml), and {gamma}c chain expression was determined by flow cytometry. The data represent one of three independent experiments.

 
To verify this result, IL-4-/- T cells were stimulated for 72 h with various concentrations of IL-4 (5–60 ng/ml) with rhIL-2 or without rhIL-2 (10 U/ml), or in the presence of rhIL-2 (5–60 U/ml) alone. The expression of IL-2R was determined by first incubation with biotinylated rhIL-2 followed by avidin-FITC. Using this approach, we should be able to directly demonstrate whether the binding capacity of IL-2 to IL-2R was up-regulated by IL-4 during induction of AICD. IL-4 itself only had a marginal effect on IL-2R expression, however, in the presence of 10 U/ml of rhIL-2, IL-4 significantly up-regulated IL-2R expression to a comparable level of rhIL-2-treated T cells (Fig. 4C, middle panel). Reciprocally, exogenous IL-4 strongly up-regulated IL-2R expression induced by low to medium levels of IL-2 (5–20 U/ml). In support of these findings, the addition of exogenous IL-4 in the absence of IL-2 did not restore defective AICD in IL-4-/- T cells (data not shown).

It has been shown that IL-4R can activate STAT-5 by a mechanism that relies upon the {gamma}c chain (44). Although we also detected increased expression of the {gamma}c chain upon IL-4 stimulation in the presence of IL-2 (Fig. 4C, right panel), this IL-4-mediated up-regulation of the {gamma}c chain expression cannot account for the restoration of defective AICD in IL-4-/- T cells as the addition of rhIL-2, but not rmIL-4, restored impaired AICD in STAT-6-/- T cells (Fig. 4B), suggesting that regulation of AICD by IL-4 is {gamma}c-independent. Taken together, our observations indicate that IL-4 can regulate the sensitivity of T cells to IL-2 during the induction of AICD possibly via the up-regulation of IL-2R expression.

The requirements of IL-2 signaling thresholds for induction of FasL expression and c-FLIP degradation are different

We have shown that at low concentrations of rhIL-2 (2 U/ml), the optimal FasL induction requires IL-4 (Fig. 2). At medium concentrations of rhIL-2 (10 U/ml), induction of AICD requires IL-4/STAT-6 signaling, whereas at high concentrations of rhIL-2 (60 U/ml), IL-4 is not required for induction of AICD (Fig. 4). Thus, these data suggest that FasL expression and induction of AICD require different thresholds for IL-2 signaling. IL-4, by some unknown mechanism, can lower this threshold. To test this hypothesis, T cells from IL-4-/- and STAT-6-/- mice were activated with plate-bound anti-CD3 and anti-CD28 mAbs in the presence of rmIL-4 with 2 or 10 U/ml rhIL-2 or in the presence of 60 U/ml rhIL-2 alone, and cells were collected at 24 and 72 h, respectively. As shown in the left panel of Fig. 5A, the addition of rmIL-4 or rhIL-2 to IL-4-/- T cells favored the degradation of c-FLIP in these cells, whereas the addition of rmIL-4 did not have any effect upon c-FLIP expression in STAT-6-/- T cells. Of note, the addition of 2 U/ml rhIL-2 did not induce any c-FLIP degradation in Wt T cells (Fig. 5A, right panel), but 10 U/ml rhIL-2 induced c-FLIP degradation (Fig. 3, B and C). Similarly, the addition of rhIL-2 also induced degradation of both c-FLIPL and c-FLIPS in STAT-6-/- T cells (Fig. 5A, left panel). Our data support the idea that the induction of FasL expression and c-FLIP degradation requires different thresholds for IL-2 signaling. To confirm this hypothesis, tyrosine phosphorylation of STAT-5 in IL-4-/- T cells, under the stimulation conditions described above, was detected. Consistent with the above data, certain levels of IL-2 are critical for IL-4-mediated STAT-5 phosphorylation. Low levels of tyrosine phosphorylation were observed in 2 U/ml rhIL-2 and 60 ng/ml rmIL-4-treated IL-4-/- T cells, whereas tyrosine phosphorylation of STAT-5 was significantly increased in rhIL-2 (10 U/ml)/rmIL-4 (60 ng/ml)-treated IL-4-/- T cells which was comparable with rhIL-2 (60 U/ml)-treated IL-4-/- T cells, further supporting our hypothesis.



View larger version (44K):
[in this window]
[in a new window]
  		FIGURE 5. Induction of FasL expression and c-FLIP degradation requires different thresholds for IL-2 signaling. A, Left panel, IL-4-/- and STAT-6-/- T cells were activated for 24 or 72 h with plate-bound anti-CD3 and anti-CD28 mAbs in the presence or absence of rmIL-4 or rhIL-2. Note that 10 U/ml rhIL-2 was added to rmIL-4-treated (60 ng/ml) IL-4-/- or STAT-6-/- T cells. Right panel, Wt T cells were activated with plate-bound anti-CD3 and anti-CD28 in the presence of 2 or 10 U/ml rhIL-2. The cells were collected at 72 h, lysed in 1% Triton X-100 lysis buffer, and lysates were blotted with anti-c-FLIPL/S mAb. The equal protein loading was confirmed by anti-actin blotting. B, Splenic T cells from IL-4-/-mice were activated for 15 and 30 min at 37°C with rmIL-4 (60 ng/ml), IL-2 (2 U/ml) and rmIL-4 (60 ng/ml), rmIL-4 (60 ng/ml), rhIL-2 (10 U/ml) plus rmIL-4 (60 ng/ml), and rhIL-2 (60 U/ml). The cells were lysed in 1% Brij 97 lysis buffer, and immunoprecipitated with anti-STAT-5 Ab. The STAT-5 immunoprecipitates were blotted with anti-phosphotyrosine (pTyr) mAb. The membranes were stripped and reprobed with anti-STAT-5 Ab. Data are shown from one of three independent experiments.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
AICD is one of the major mechanisms for maintaining peripheral tolerance in T cells, and is dependent upon the interaction between Fas and FasL (7, 9, 37, 45). In this study, we demonstrate that AICD in IL-4-/- T cells is impaired, and this impaired AICD cannot be ascribed to the defective expression of FasL or Bcl-2 and Bcl-xL, but rather correlates with the failure of down-regulation of c-FLIP expression. IL-4 favors T cells undergoing AICD by inducing degradation of c-FLIP, and this effect requires signaling through STAT-6. Most importantly, our data indicate that IL-4 regulates the susceptibility of T cells to AICD by influencing T cell sensitivity to IL-2.

Although several studies suggest that cytokines play an important role in T cell apoptosis, the roles of IL-4 in AICD remain to be further elucidated. We found that AICD was defective in IL-4-/- T cells. The addition of rmIL-4 was able to restore the defective AICD in IL-4-/- T cells (Fig. 4B). Interestingly, IL-4-mediated restoration of AICD in IL-4-/- T cells correlates with increased degradation of c-FLIP. These findings indicate that IL-4 is an enhancer of AICD and that IL-4-mediated enhancement of AICD is through the regulation of c-FLIP expression. Note that our observations were similar to those described by Refaeli et al. (37) who found that in IL-2-/- T cells, c-FLIP expression was maintained in activated T cells. This raised the possibility that the enhancement of AICD in IL-4-/- T cells by IL-4 might be mediated by IL-2. Although IL-2 production during the primary stimulation with anti-CD3 and anti-CD28 was equivalent in Wt and IL-4-/- T cells, it remains possible that in the absence of IL-4, T cell sensitivity to IL-2 might decrease. This possibility is supported because 1) the addition of rhIL-2 can restore the susceptibility of IL-4-/- T cells to AICD (Fig. 4B) and favor c-FLIP degradation (Fig. 5A); 2) IL-4-mediated enhancement of AICD in IL-4-/- T cells could be blocked completely by a neutralizing anti-IL-2 mAb (Fig. 4B); 3) IL-4 significantly augments IL-2-mediated IL-2R expression during induction of AICD (Fig. 4C); and 4) induction of FasL expression and c-FLIP degradation may require different thresholds for IL-2 signaling (Fig. 5). Taken together, our observations suggest that the enhancement of AICD in IL-4-/- T cells by IL-4 is mediated by the up-regulation of T cell sensitivity to IL-2. Although the regulation of IL-2R by IL-4 remains controversial (46, 47, 48, 49, 50), our data are consistent with those that find that IL-4 can up-regulate the expression of IL-2R{alpha} and IL-2R{beta} (46, 47).

The role of c-FLIP in Fas-mediated cell death is still controversial. It was reported that IL-2 can sensitize T cells without affecting expression levels of c-FLIP in primary human T cells (40). Studies using c-FLIPL transgenic mice revealed that c-FLIPL suppresses FasL-induced T cell apoptosis but not AICD (51). Several possibilities may explain why AICD is not impaired in c-FLIPL transgenic mice. First, c-FLIPS may be the major isoform responsible for regulating the susceptibility of T cells to AICD (29, 42). In support of this notion, c-FLIPS, but not c-FLIPL, completely blocks the cleavage of pro-caspase-8 at the DISC (52). Consistent with this notion, our data showed that c-FLIPL Tg T cells are not completely resistant to FasL-induced T cell death (Fig. 3E), Second, the levels of transgenic c-FLIPL in T cells may not be sufficient to block caspase-8 activation required for AICD. It has been shown that c-FLIPL expression at low levels enhances pro-caspase-8 processing at the DISC, whereas at high levels inhibits Fas-mediated apoptosis (53). The role of c-FLIP in the regulation of AICD in vitro and in vivo has also been strongly supported by the following evidence: retrovirus-mediated overexpression of c-FLIP blocks Fas-induced apoptosis of activated T and B cells, which leads to the production of autoantibodies and to the development of autoimmune diseases (54). Consistent with this finding, it has recently been shown that c-FLIP may be involved in controlling lymphoadenopathy in IL-2-/- mice (55). These observations suggest that the modulation of c-FLIP is necessary to maintain self-tolerance. In support of these findings, c-FLIP-/- cells are specifically sensitive to death receptor-induced apoptosis (56). Most importantly, we have shown that T cells overexpressing c-FLIPL are resistant to Fas-mediated T cell death, supporting the involvement of c-FLIP in Fas-mediated cell death (Fig. 3E). Taken together, these findings suggest that c-FLIP does regulate T cell susceptibility to Fas-mediated AICD.

The regulation of c-FLIP expression is not fully understood. In FasL-responding T cells activated for 6 days, the level of c-FLIPL had decreased considerably, whereas c-FLIPS was not detected, despite the presence of high c-FLIPS RNA. These results suggest that c-FLIP may be controlled at the posttranscriptional level (19). Using IL-2-/- T cells, Refaeli et al. (37) reported that IL-2 controls c-FLIP expression at the transcriptional level. However, using the real-time RT-PCR technique, we found no decrease, but a slight increase, in c-FLIPL and c-FLIPS expression. More importantly, our results using a mAb against c-FLIPL and c-FLIPS clearly indicate that IL-4 controls c-FLIP expression at the posttranslational level and therefore regulates T cell sensitivity to IL-2. Our observations are consistent with those reported by Irmler et al. (19) but differ from those observed by Refaeli et al. (37) who reported that IL-2 controls c-FLIP expression at the transcriptional level. The discrepancy between our data and those by Refaeli et al. (37) is currently unknown.

Our data suggest that the requirement of the thresholds for IL-2 signaling in induction of FasL and c-FLIP degradation is different. This notion is supported by the evidence that a lower level of rhIL-2 (2 U/ml) is sufficient to induce FasL expression, but not c-FLIP degradation (Fig. 5A, left panel), whereas a medium level of rhIL-2 (10 U/ml) can induce similar levels of FasL expression and c-FLIP degradation (Figs. 2 and 5A). Our data of IL-4 regulating IL-2 signaling is consistent with the recent exciting observation that a STAT-6 inducible gene can enhance the responsiveness of T cells to IL-2 for growth (57).

The consequence of a defect in AICD is the development of autoimmune lymphoproliferative disease in Fas/FasL-/-, IL-2-/-, IL-2R{alpha}-/-, and IL-2R{beta}-/- mice (58, 59, 60, 61, 62, 63). However, this phenotype is not observed either in IL-4-/- or STAT-6-/- mice (33, 64). This could be explained by the fact that IL-2 is a critical cytokine which regulates T cell susceptibility to AICD, and under certain circumstances IL-4 can affect AICD and this effect is achieved by an IL-2-dependent mechanism.

It has been shown that c-FLIP and caspase-8 are recruited to the DISC, but after initial cleavage of both molecules following Fas ligation, the cleavage intermediates are bound to the receptor and can no longer be replaced by pro-caspase-8 (40, 42, 52). However, all these data were generated from BJAB cells transfected with c-FLIP constructs. Using primary mouse T cells, we found that IL-4 down-regulates the T cell threshold for IL-2 signaling, thus promoting c-FLIP degradation induced by caspases (possibly by caspase-8) (19, 40). IL-4 indirectly controls the amounts of c-FLIP including full-length c-FLIPL, its p43 intermediates, and c-FLIPS recruited to the DISC after Fas ligation, thus regulating pro-caspase-8 activation. Our data also suggest that both c-FLIPL and c-FLIPS are involved in the regulation of susceptibility of mouse T cells to AICD. Consistent with this idea, a small but significant number of T cells overexpressing c-FLIPL still undergo apoptosis, suggesting that c-FLIPS plays a role in Fas-mediated cell death.

Because IL-4-dependent gene activation involves activation of STAT-6 (1, 65), it was crucial to determine whether the impairment in AICD in IL-4-/- T cells was dependent upon the JAK/STAT-6 signaling pathway. Our data showed that T cells from STAT-6-/- mice were resistant to AICD. The addition of exogenous IL-4 restored AICD in IL-4-/- T cells but not in STAT-6-/- T cells. These two pieces of evidence clearly indicate that the JAK/STAT-6 signaling pathway is required for IL-4-mediated enhancement of AICD.

In summary, our observations indicate that IL-4 is involved in the regulation of the susceptibility of T cells to AICD. IL-4 promotes AICD via inducing degradation of c-FLIP, which then increases the susceptibility of T cells to AICD. The regulation of AICD susceptibility by IL-4 requires the signal through STAT-6. The effects of IL-4 on AICD may be achieved by down-regulating the thresholds of T cells for IL-2 signaling. Our data suggest that IL-4 potentiates AICD by an IL-2-dependent mechanism.


   Acknowledgments
 
We are grateful to Drs. V. Adarichev and G. Firneisz for their advice on real-time RT-PCR analysis, Dr. M. J. Grusby for kindly providing STAT-6-/- mice, Drs. T. L. Delovitch, M. J. Grusby, and X. Lin for their critical comments on the manuscript, and S. Velins for her valuable assistance in the preparation of this manuscript.


   Footnotes
 
1 This work was supported in part by National Institutes of Health Grants AR47412 and AR49047 (to J.Z.), AR40310 (to T.T.G.), and AR45652 (to T.T.G., K.M., and A.F.), and an Arthritis National Research Foundation Grant (to J.Z.). Back

2 Address correspondence and reprint requests to Dr. Jian Zhang, Department of Orthopedic Surgery, Rush-Presbyterian-St. Luke’s Medical Center, Cohn Research Building, Room 724, 1735 West Harrison Street, Chicago, IL 60612. E-mail address: jzhang1{at}rush.edu Back

3 T.B. and Q.S. contributed equally to this work. Back

4 Abbreviations used in this paper: {gamma}c, common {gamma} chain; JAK, Janus kinase; IRS, insulin receptor substrate; AICD, activation-induced cell death; FasL, Fas ligand; FADD, Fas-associated death domain; DISC, death-inducing signaling complex; Wt, wild type; Tg, transgenic; rh, recombinant human; rm, recombinant mouse; PI, propidium iodide; CT, cycle threshold; c-FLIP, cellular FLIP. Back

Received for publication October 28, 2002. Accepted for publication January 21, 2003.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Nelms, K., A. D. Keegan, J. Zamorano, J. J. Ryan, W. E. Paul. 1999. The IL-4 receptor: signaling mechanisms and biologic functions. Annu. Rev. Immunol. 17:701.[Medline]
  2. Imada, K., W. J. Leonard. 2000. The Jak-STAT pathway. Mol. Immunol. 37:1.[Medline]
  3. Wurster, A. L., T. Tanaka, M. J. Grusby. 2000. The biology of Stat4 and Stat6. Oncogene 19:2577.[Medline]
  4. Gessner, A., M. Rollinghoff. 2000. Biologic functions and signaling of the interleukin-4 receptor complexes. Immunobiology 201:285.[Medline]
  5. Nelms, K., H. Huang, J. Ryan, A. Keegan, W. E. Paul. 1998. Interleukin-4 receptor signalling mechanisms and their biologic significance. Adv. Exp. Med. Biol. 452:37.[Medline]
  6. Ihle, J. N., T. Nosaka, W. Thierfelder, F. W. Quelle, K. Shimoda. 1997. Jaks and Stats in cytokine signaling. Stem Cells 15:S105.
  7. Varadhachary, A. S., S. N. Perdow, C. Hu, M. Ramanarayanan, P. Salgame. 1997. Differential ability of T cell subsets to undergo activation-induced cell death. Proc. Natl. Acad. Sci. USA 94:5778.[Abstract/Free Full Text]
  8. van Parijs, L., Y. Refaeli, J. D. Lord, B. H. Nelson, A. K. Abbas, D. Baltimore. 1999. Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death. Immunity 11:281.[Medline]
  9. Zhang, J., J.-X. Gao, K. Salojin, Q. Shao, M. Grattan, C. Meagher, D. W. Laird, T. L. Delovitch. 2000. Regulation of Fas ligand expression during activation-induced cell death in T cells by p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase. J. Exp. Med. 191:1017.[Abstract/Free Full Text]
  10. Alderson, M. R., T. W. Tough, T. Davis-Smith, S. Braddy, B. Falk, K. A. Schooley, R. G. Goodwin, C. A. Smith, F. Ramsdell, D. H. Lynch. 1995. Fas ligand mediates activation-induced cell death in human T lymphocytes. J. Exp. Med. 181:71.[Abstract/Free Full Text]
  11. Ashkenazi, A., V. M. Dixit. 1999. Apoptosis control by death and decoy receptors. Curr. Opin. Cell Biol. 11:255.[Medline]
  12. Hildeman, D. A., Y. Zhu, T. C. Mitchell, J. Kappler, P. Marrack. 2002. Molecular mechanisms of activated T cell death in vivo. Curr. Opin. Immunol. 14:354.[Medline]
  13. Kabelitz, D., O. Janssen. 1997. Antigen-induced death of T-lymphocytes. Front. Biosci. 2:61.
  14. Wolf, B. B., D. R. Green. 1999. Suicidal tendencies: apoptotic cell death by caspase family proteinases. J. Biol. Chem. 274:20049.[Free Full Text]
  15. Nagata, S., P. Golstein. 1995. The Fas death factor. Science 267:1449.[Abstract/Free Full Text]
  16. Nagata, S.. 1997. Apoptosis by death factor. Cell 88:355.[Medline]
  17. Ashkenzi, A., V. M. Dixit. 1998. Death receptors: signaling and modulation. Science 281:1305.[Abstract/Free Full Text]
  18. Thome, M., P. Schneider, K. Hofmann, H. Fickenscher, E. Meinl, F. Neipel, C. Mattmann, K. Burns, J.-L. Bodmer, M. Schröter, et al 1997. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386:517.[Medline]
  19. Irmler, M., M. Thome, M. Hahne, P. Schneider, K. Hofmann, V. Steiner, J.-L. Bodmer, M. Schröter, K. Burns, C. Mattmann, et al 1997. Inhibition of death receptor signals by cellular FLIP. Nature 388:190.[Medline]
  20. Shu, H.-B., D. R. Halpin, D. V. Goeddel. 1997. Casper is a FADD- and Caspase-related inducer of apoptosis. Immunity 6:751.[Medline]
  21. Hu, S., C. Vincenz, J. Ni, R. Gentz, V. M. Dixit. 1997. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis. J. Biol. Chem. 272:17255.[Abstract/Free Full Text]
  22. Han, D. K., P. M. Chaudhary, M. E. Wright, C. Friedman, B. J. Trask, R. T. Riedel, D. G. Baskin, S. M. Schwartz, L. Hood. 1997. MRIT, a novel death-effector domain-containing protein, interacts with caspases and Bcl-xL and initiates cell death. Proc. Natl. Acad. Sci. USA 94:11333.[Abstract/Free Full Text]
  23. Goltsev, Y. V., A. V. Kovalenko, E. Arnold, E. E. Varfolomeev, V. M. Brodianskii, D. Wallach. 1997. CASH, a novel caspase homologue with death effector domains. J. Biol. Chem. 272:19641.[Abstract/Free Full Text]
  24. Srinivasula, S. M., M. Ahmad, S. Ottilie, F. Bullrich, S. Banks, Y. Wang, T. Fernandes-Alnemri, C. M. Croce, G. Litwack, K. J. Tomaselli, et al 1997. FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis. J. Biol. Chem. 272:18542.[Abstract/Free Full Text]
  25. Inohara, N., T. Koseki, Y. Hu, S. Chen, G. Nunez. 1997. CLARP, a death effector domain-containing protein interacts with caspase-8 and regulates apoptosis. Proc. Natl. Acad. Sci. USA 94:10717.[Abstract/Free Full Text]
  26. Rasper, D. M., J. P. Vaillancourt, S. Hadano, V. M. Houtsager, I. Seiden, S. L. Keen, P. Tawa, S. Xanthoudakis, J. Nasir, D. Martindale, et al 1998. Cell death attenuation by "Usurpin," a mammalian DED-caspase homologue that precludes caspase-8 recruitment and activation by the CD-95 (Fas, APO-1) receptor complex. Cell Death Differ. 5:271.[Medline]
  27. Wang, J., A. A. Lobito, F. Shen, F. Hornung, A. Winoto, M. J. Lenardo. 2000. Inhibition of Fas-mediated apoptosis by the B cell antigen receptor through c-FLIP. Eur. J. Immunol. 30:155.[Medline]
  28. Tschopp, J., M. Irmler, M. Thome. 1998. Inhibition of Fas death signals by FLIPs. Curr. Opin. Cell Biol. 10:552.
  29. Kirchhoff, S., W. W. Müller, M. Li-Weber, P. H. Krammer. 2000. Up-regulation of c-FLIPshort and reduction of activation-induced cell death in CD28-co-stimulated human T cells. Eur. J. Immunol. 30:2765.[Medline]
  30. van Parijs, L., A. Biuckians, A. Ibragimov, F. W. Alt, D. M. Willerford, A. K. Abbas. 1997. Functional responses and apoptosis of CD25 (IL-2R{alpha})- deficient T cells expressing a transgenic antigen receptor. J. Immunol. 158:3738.[Abstract]
  31. Zheng, L., C. L. Trageser, D. M. Willerford, M. J. Lenardo. 1998. T cell growth cytokines cause the superinduction of molecules mediating antigen-induced T lymphocyte death. J. Immunol. 160:763.[Abstract/Free Full Text]
  32. Kung, J. T., D. Beller, S.-T. Ju. 1998. Lymphokine regulation of activation-induced apoptosis in T cells of IL-2 and IL-2R{beta} knockout mice. Cell. Immunol. 185:158.[Medline]
  33. Kaplan, M. H., U. Schindler, S. T. Smiley, M. J. Grusby. 1996. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 4:313.[Medline]
  34. Kataoka, T., R. C. Budd, N. Holler, M. Thome, F. Martinon, M. Irmler, K. Burns, M. Hahne, N. Kennedy, M. Kovacsovics, J. Tschopp. 2000. The caspase-8 inhibitor FLIP promotes activation of NF-{kappa}B and Erk signaling pathways. Curr. Biol. 10:640.[Medline]
  35. Zhang, J., T. Bárdos, K. Mikecz, A. Finnegan, T. T. Glant. 2001. Impaired Fas signaling pathway is involved in defective T cell apoptosis in autoimmune arthritis. J. Immunol. 166:4981.[Abstract/Free Full Text]
  36. Lissy, N. A., L. F. van Dyk, M. Becker-Hapak, A. Vocero-Akbani, J. H. Mendler, S. F. Dowdy. 1998. TCR antigen-induced cell death occurs from a late G1 phase cell cycle check point. Immunity 8:57.[Medline]
  37. Refaeli, Y., L. V. Parijs, C. A. London, J. Tschopp, A. K. Abbas. 1998. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 8:615.[Medline]
  38. Vella, A., T. K. Teague, J. Ihle, J. Kappler, P. Marrack. 1997. Interleukin 4 (IL-4) or IL-7 prevents the death of resting T cells: stat6 is probably not required for the effect of IL-4. J. Exp. Med. 186:325.[Abstract/Free Full Text]
  39. Vella, A. T., S. Dow, T. A. Potter, J. Kappler, P. Marrack. 1998. Cytokine-induced survival of activated T cells in vitro and in vivo. Proc. Natl. Acad. Sci. USA 95:3810.[Abstract/Free Full Text]
  40. Scaffidi, C., I. Schmitz, P. H. Krammer, M. E. Peter. 1999. The role of c-FLIP in modulation of CD95-induced apoptosis. J. Biol. Chem. 274:1541.[Abstract/Free Full Text]
  41. Yoshikawa, H., Y. Nakamaru, K. Tasaka. 2000. Enhanced expression of Fas-associated death domain-like IL-1-converting enzyme (FLICE)-inhibitory protein induces resistance to Fas-mediated apoptosis in activated mast cells. J. Immunol. 165:6262.[Abstract/Free Full Text]
  42. Kirchhoff, S., W. W. Müller, A. Krueger, I. Schmitz, P. H. Krammer. 2000. TCR-mediated up-regulation of c-FLIPshort correlates with resistance toward CD95-mediated apoptosis by blocking death-inducing signaling complex activity. J. Immunol. 165:6293.[Abstract/Free Full Text]
  43. Lenardo, M. J.. 1991. Interleukin-2 programs mouse {alpha}{beta} T lymphocytes for apoptosis. Nature 353:858.[Medline]
  44. Lischke, A., R. Moriggl, S. Brandlein, S. Berchtold, W. Kammer, W. Sebald, B. Groner, X. Liu, L. Hennighausen, K. Friedrich. 1998. The interleukin-4 receptor activates STAT5 by a mechanism that relies upon common {gamma}-chain. J. Biol. Chem. 273:31222.[Abstract/Free Full Text]
  45. Boehme, S. A., M. J. Lenardo. 1993. Propriocidal apoptosis of mature T lymphocytes occurs at S phase of the cell cycle. Eur. J. Immunol. 23:1552.[Medline]
  46. Froussard, P., D. L. Jankovic, P. Chastagner, J. Theze. 1991. Induction of mouse p55 interleukin-2 receptor gene expression by IL-2 and IL-4 and characterization of its transcription initiation sites. Mol. Immunol. 28:87.[Medline]
  47. Casey, L. S., A. H. Lichtman, M. Boothby. 1992. IL-4 induces IL-2 receptor p75 {beta}-chain gene expression and IL- 2-dependent proliferation in mouse T lymphocytes. J. Immunol. 148:3418.[Abstract]
  48. Gaya, A., O. de la Calle, J. Yague, E. Alsinet, M. D. Fernandez, M. Romero, V. Fabregat, J. Martorell, J. Vives. 1991. IL-4 inhibits IL-2 synthesis and IL-2-induced up-regulation of IL-2R {alpha} but not IL-2R {beta} chain in CD4+ human T cells. J. Immunol. 146:4209.[Abstract]
  49. Martinez, O. M., R. S. Gibbons, M. R. Garovoy, F. R. Aronson. 1990. IL-4 inhibits IL-2 receptor expression and IL-2-dependent proliferation of human T cells. J. Immunol. 144:2211.[Abstract]
  50. Jankovic, D. L., M. Gilbert, D. Baran, J. Ohara, W. E. Paul, J. Theze. 1989. Activation by IL-2, but not IL-4, up-regulates the expression of the p55 subunit of the IL-2 receptor on IL-2- and IL-4-dependent T cell lines. J. Immunol. 142:3113.[Abstract]
  51. Lens, S. M., T. Kataoka, K. A. Fortner, A. Tinel, I. Ferrero, R. H. MacDonald, M. Hahne, F. Beermann, A. Attinger, H. A. Orbea, et al 2002. The caspase 8 inhibitor c-FLIPL modulates T-cell receptor-induced proliferation but not activation-induced cell death of lymphocytes. Mol. Cell. Biol. 22:5419.[Abstract/Free Full Text]
  52. Krueger, A., I. Schmitz, S. Baumann, P. H. Krammer, S. Kirchhoff. 2001. Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J. Biol. Chem. 276:20633.[Abstract/Free Full Text]
  53. Chang, D. W., Z. Xing, Y. Pan, A. Algeciras-Schimnich, B. C. Barnhart, S. Yaish-Ohad, M. E. Peter, X. Yang. 2002. c-FLIPL is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J. 21:3704.[Medline]
  54. van Parijs, L., Y. Refaeli, A. K. Abbas, D. Baltimore. 1999. Autoimmunity as a consequence of retrovirus-mediated expression of c-FLIP in lymphocytes. Immunity 11:763.[Medline]
  55. Chastagner, P., J. Reddy, J. Theze. 2002. Lymphoadenopathy in IL-2-deficient mice: further characterization and overexpression of the antiapoptotic molecule cellular FLIP. J. Immunol. 169:3644.[Abstract/Free Full Text]
  56. Yeh, W.-C., A. Itie, A. J. Elia, M. Ng, H.-B. Shu, A. Wakeham, C. Mirtsos, N. Suziki, M. Bonnard, D. V. Goeddel, T. W. Mak. 2000. Requirement for casper (c-FLIP) in regulation of death receptor- induced apoptosis and embryonic development. Immunity 12:633.[Medline]
  57. Zhu, J., L. Guo, B. Min, C. J. Watson, J. Hu-Li, H. A. Young, P. N. Tsichlis, W. E. Paul. 2002. Growth factor independent-1 induced by IL-4 regulates Th2 cell proliferation. Immunity 16:733.[Medline]
  58. Watanabe-Fukunaga, R., C. I. Brannan, N. G. Copeland, N. A. Jenkins, S. Nagata. 1992. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314.[Medline]
  59. Sadlack, B., J. Lohler, H. Schorle, G. Klebb, H. Haber, E. Sickel, R. J. Noelle, I. Horak. 1995. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur. J. Immunol. 25:3053.[Medline]
  60. Klebb, G., I. B. Autenrieth, H. Haber, E. Gillert, B. Sadlack, K. A. Smith, I. Horak. 1996. Interleukin-2 is indispensable for development of immunological self-tolerance. Clin. Immunol. Immunopathol. 81:282.[Medline]
  61. Suzuki, H., T. M. Kundig, C. Furlonger, A. Wakeham, E. Timms, T. Matsuyama, R. Schmits, J. J. Simard, P. S. Ohashi, H. Griesser, et al 1995. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor {beta}. Science 268:1472.[Abstract/Free Full Text]
  62. Ramsdell, F., M. S. Seaman, R. E. Miller, T. W. Tough, M. R. Alderson, D. H. Lynch. 1994. gld/gld mice are unable to express a functional ligand for Fas. Eur. J. Immunol. 24:928.[Medline]
  63. Lynch, D. H., M. L. Watson, M. R. Alderson, P. R. Baum, R. E. Miller, T. Tough, M. Gibson, T. Davis-Smith, C. A. Smith, K. Hunter. 1994. The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity. 1:131.[Medline]
  64. Noben-Trauth, N., W. E. Paul, D. L. Sacks. 1999. IL-4-and IL-4 receptor-deficient BALB/c mice reveal differences in susceptibility to Leishmania major parasite substrains. J. Immunol. 162:6132.[Abstract/Free Full Text]
  65. Linehan, L. A., W. D. Warren, P. A. Thompson, M. J. Grusby, M. T. Berton. 1998. STAT6 is required for IL-4-induced germline Ig gene transcription and switch recombination. J. Immunol. 161:302.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Int ImmunolHome page
F. Boldizsar, O. Tarjanyi, P. Nemeth, K. Mikecz, and T. T. Glant
Th1/Th17 polarization and acquisition of an arthritogenic phenotype in arthritis-susceptible BALB/c, but not in MHC-matched, arthritis-resistant DBA/2 mice
Int. Immunol., May 1, 2009; 21(5): 511 - 522.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. Zhang, G. Xu, L. Zhang, A. I. Roberts, and Y. Shi
Th17 Cells Undergo Fas-Mediated Activation-Induced Cell Death Independent of IFN-{gamma}
J. Immunol., July 1, 2008; 181(1): 190 - 196.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. B. S. King, A. M. Knorn, C. Ohnmacht, and D. Voehringer
Accumulation of Effector CD4 T Cells during Type 2 Immune Responses Is Negatively Regulated by Stat6
J. Immunol., January 15, 2008; 180(2): 754 - 763.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
K. J. Rautajoki, E. M. Marttila, T. A. Nyman, and R. Lahesmaa
Interleukin-4 Inhibits Caspase-3 by Regulating Several Proteins in the Fas Pathway during Initial Stages of Human T Helper 2 Cell Differentiation
Mol. Cell. Proteomics, February 1, 2007; 6(2): 238 - 251.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. C. Morris, T. Orekhova, M. J. Meadows, S. M. Heidorn, J. Yang, and F. D. Finkelman
IL-4 Induces In Vivo Production of IFN-{gamma} by NK and NKT Cells
J. Immunol., May 1, 2006; 176(9): 5299 - 5305.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
S. Korten, R. J. Anderson, C. M. Hannan, E. G. Sheu, R. Sinden, S. Gadola, M. Taniguchi, and A. V. S. Hill
Invariant V{alpha}14 Chain NKT Cells Promote Plasmodium berghei Circumsporozoite Protein-Specific Gamma Interferon- and Tumor Necrosis Factor Alpha-Producing CD8+ T Cells in the Liver after Poxvirus Vaccination of Mice
Infect. Immun., February 1, 2005; 73(2): 849 - 858.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, J.
Right arrow Articles by Finnegan, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, J.
Right arrow Articles by Finnegan, A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS